Last updated: 9 February 2023 at 5:25pm EST

Rock Ventures Iv, L.P.Third... Net Worth




The estimated Net Worth of Rock Ventures Iv, L.P.Third... is at least $130 Million dollars as of 7 February 2023. Rock Third owns over 3,700,000 units of Revolution Medicines Inc stock worth over $127,404,779 and over the last 6 years Rock sold RVMD stock worth over $3,071,000.

Rock Third RVMD stock SEC Form 4 insiders trading

Rock has made over 2 trades of the Revolution Medicines Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Rock sold 3,700,000 units of RVMD stock worth $3,071,000 on 7 February 2023.

The largest trade Rock's ever made was selling 3,700,000 units of Revolution Medicines Inc stock on 7 February 2023 worth over $3,071,000. On average, Rock trades about 756,250 units every 259 days since 2018. As of 7 February 2023 Rock still owns at least 3,058,204 units of Revolution Medicines Inc stock.

You can see the complete history of Rock Third stock trades at the bottom of the page.



Insiders trading at Revolution Medicines Inc

Over the last 5 years, insiders at Revolution Medicines Inc have traded over $249,645,422 worth of Revolution Medicines Inc stock and bought 3,371,315 units worth $74,500,278 . The most active insiders traders include Peter Svennilson, Thilo Schroeder und Rock Ventures Ii, L.P.Third.... On average, Revolution Medicines Inc executives and independent directors trade stock every 11 days with the average trade being worth of $3,075,216. The most recent stock trade was executed by Stephen Michael Kelsey on 13 August 2024, trading 16,667 units of RVMD stock currently worth $68,168.



What does Revolution Medicines Inc do?

revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.



Complete history of Rock Third stock trades at Magenta Therapeutics Inc, Fulcrum Therapeutics Inc und Revolution Medicines Inc

Insider
Trans.
Transaktion
Gesamtpreis
Rock Ventures Iv, L.P.Third...
Verkauf $3,071,000
7 Feb 2023
Rock Ventures Iv, L.P.Third...
Kauf $1,300,000
22 Jul 2019


Revolution Medicines Inc executives and stock owners

Revolution Medicines Inc executives and other stock owners filed with the SEC include: